Key Takeaways
- • Bireme Capital purchased Moderna shares in April 2025 at approximately $25 per share, representing a significant contrarian bet on a company trading 95% below its pandemic-era peak despite sector-wide biotech undervaluation.
- • The stock delivered a 177% return following a major single-day gain described as the largest for an S&P 500 constituent this century, prompting Bireme to exit the majority of its position in the $140s on Wednesday (late August 2026).
- • Bireme identified an asymmetric payoff opportunity driven by excessive negative sentiment and policy headwinds, including Trump administration attacks on mRNA technology, that created a divergence between stock price and expected value despite Moderna's atypical cash-burn characteristics.
- • By April 2025, approximately 25% of the Nasdaq Biotechnology Index traded below cash on balance sheets—a record proportion—creating broad sector dislocation that positioned Moderna as uniquely undervalued relative to its diversified pipeline and oncology upside potential.
- • The investment thesis relied on identifying behavioral investor bias and market mispricing rather than deep biotech expertise, consistent with Bireme's core contrarian value strategy.
Summary
Bireme Capital executed a high-conviction contrarian investment in Moderna in April 2025, purchasing shares at approximately $25 per share despite acknowledging the position represented a departure from the firm's historical investment discipline. The hedge fund recognized that Moderna, while exhibiting characteristics typically avoided in biotech—specifically substantial cash burn from R&D spending predicated on unsustainable pandemic-era revenue levels—offered an atypical opportunity created by severe market mispricing and policy-driven sentiment headwinds.
The investment thesis centered on the recognition that biotech broadly, and Moderna specifically, had become dramatically undervalued following the post-pandemic crash. By April 2025, approximately one-quarter of the Nasdaq Biotechnology Index traded below the cash holdings on their balance sheets, representing a historical record proportion. Moderna found itself at the epicenter of broader sector dislocation, compounded by the new Trump administration's public attacks on and defunding of mRNA technology, despite its proven efficacy in respiratory applications and substantial promise in oncology development.
Bireme differentiated Moderna from the broader uninvestable biotech universe by identifying that its pipeline extended beyond the idiosyncratic, specialized drug development that typically characterizes high-risk biotech investments. Rather than requiring deep sector expertise, the investment represented an identification of unloved assets where excessive negative sentiment had created clear divergence between stock price and expected value—a core competency for the firm's contrarian value approach.
The position generated exceptional returns, delivering a 177% gain before Bireme liquidated the majority of its holdings in the $140s during late August 2026, following what was characterized as the largest single-day stock gain for an S&P 500 constituent this century. The exit crystallized gains from an investment held approximately 16 months, validating the firm's thesis that market-driven sentiment dislocation and policy-driven headwinds had created a material mispricing opportunity in a company whose underlying asset base remained intact despite near-term operational challenges.
The investment thesis centered on the recognition that biotech broadly, and Moderna specifically, had become dramatically undervalued following the post-pandemic crash. By April 2025, approximately one-quarter of the Nasdaq Biotechnology Index traded below the cash holdings on their balance sheets, representing a historical record proportion. Moderna found itself at the epicenter of broader sector dislocation, compounded by the new Trump administration's public attacks on and defunding of mRNA technology, despite its proven efficacy in respiratory applications and substantial promise in oncology development.
Bireme differentiated Moderna from the broader uninvestable biotech universe by identifying that its pipeline extended beyond the idiosyncratic, specialized drug development that typically characterizes high-risk biotech investments. Rather than requiring deep sector expertise, the investment represented an identification of unloved assets where excessive negative sentiment had created clear divergence between stock price and expected value—a core competency for the firm's contrarian value approach.
The position generated exceptional returns, delivering a 177% gain before Bireme liquidated the majority of its holdings in the $140s during late August 2026, following what was characterized as the largest single-day stock gain for an S&P 500 constituent this century. The exit crystallized gains from an investment held approximately 16 months, validating the firm's thesis that market-driven sentiment dislocation and policy-driven headwinds had created a material mispricing opportunity in a company whose underlying asset base remained intact despite near-term operational challenges.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.